Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?
Therapeutic strategies targeting the programmed cell death-ligand 1/programmed cell death-1 pathway have shown significant responses and good tolerability in solid malignancies. Although preclinical studies suggest that inhibiting programmed cell death-ligand 1/programmed cell death-1 interactions might also be highly effective in hematological malignancies, remarkably few clinical trials have been published. Determining patients who will benefit most from programmed cell death-ligand 1/programmed cell death-1-directed immunotherapy and whether programmed cell death-ligand 1/programmed cell death-1 are adequate prognostic markers becomes an increasingly important clinical question, especially as aberrant programmed cell death-ligand 1/programmed cell death-1 expression are key mediators of impaired anti-tumor immune responses in a range of B-cell lymphomas. Herein, we systematically review the published literature on the expression and prognostic value of programmed cell death-ligand 1/programmed cell death-1 in these patients and identify considerable differences in expression patterns, distribution and numbers of programmed cell death-ligand 1+/programmed cell death-1+cells, both between and within lymphoma subtypes, which is reflected in conflicting findings regarding the prognostic value of programmed cell death-ligand 1+/programmed cell death-1+cells. This can be partly explained by differences in methodologies (techniques, protocols, cutoff values) and definitions of positivity. Moreover, lymphomagenesis, disease progression, and prognosis appear to be determined not only by the presence, numbers and distribution of specific subtypes of T cells, but also by other cells and additional immune checkpoints. Collectively, our findings indicate that programmed cell death-ligand 1/programmed cell death-1 interactions play an essential role in B-cell lymphoma biology and are of clinical importance, but that the overall outcome is determined by additional components. To categorize the exact prognostic value of programmed cell death-ligand 1/programmed cell death-1 expressing cells and cell types, efforts should be made to harmonize their assessment and interpretation, optimally within ongoing clinical immune checkpoint inhibitor trials, and to identify and validate novel high-throughput platforms.
Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Fabienne
F
McClanahan
Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK.
Thomas G
TG
Sharp
Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK j.gribben@qmul.ac.uk.
John G
JG
Gribben
D060890:B7-H1 Antigen / Q000032:analysis / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis / Q000378:metabolism*
D060890:B7-H1 Antigen; D061026:Programmed Cell Death 1 Receptor
Nature. 2014 Nov 27;515(7528):563-7
25428504
Blood. 2010 Oct 28;116(17):3268-77
20628145
Haematologica. 2013 Jun;98(6):953-63
23300177
Dis Markers. 2010;29(1):47-53
20826917
J Exp Med. 2003 Sep 15;198(6):851-62
12975453
J Clin Oncol. 2015 Jun 20;33(18):2004-12
25897158
Haematologica. 2015 Mar;100(3):363-9
25425693
Blood. 2014 Jul 31;124(5):750-60
24850760
Blood. 2013 Oct 17;122(16):2856-63
24004665
J Hematol Oncol. 2013 Sep 30;6(1):74
24283718
Ann Hematol. 2015 Sep;94(9):1545-52
26004934
Lancet. 2014 Sep 20;384(9948):1109-17
25034862
N Engl J Med. 2012 Jun 28;366(26):2443-54
22658127
Blood. 2014 Mar 27;123(13):2062-5
24497532
Blood Cancer J. 2015 Feb 20;5:e281
25700246
Hematology Am Soc Hematol Educ Program. 2013;2013:151-7
24319176
Blood. 2012 Aug 16;120(7):1412-21
22547582
Hum Pathol. 2012 Dec;43(12):2274-81
22795355
Haematologica. 2008 Feb;93(2):193-200
18223287
Blood. 2015 Nov 5;126(19):2193-201
26239088
Am J Surg Pathol. 2008 Aug;32(8):1252-7
18594468
Semin Cancer Biol. 2014 Feb;24:71-81
24018164
Hum Pathol. 2008 Jul;39(7):1050-8
18479731
Ann N Y Acad Sci. 2011 Jan;1217:45-59
21276005
J Clin Oncol. 2013 Nov 20;31(33):4199-206
24127452
Hum Pathol. 2011 Apr;42(4):552-7
21237493
Nat Rev Immunol. 2008 Jun;8(6):467-77
18500231
J Clin Oncol. 2013 Jul 20;31(21):2654-61
23775959
Leukemia. 2012 May;26(5):1053-63
22015774
J Clin Oncol. 2006 Nov 1;24(31):5052-9
17033038
Clin Cancer Res. 2014 Jun 1;20(11):2862-72
24727328
N Engl J Med. 2015 Jan 22;372(4):311-9
25482239
Blood. 2010 Jan 14;115(2):289-95
19901260
N Engl J Med. 2004 Nov 18;351(21):2159-69
15548776
N Engl J Med. 2015 Nov 5;373(19):1803-13
26406148
Clin Cancer Res. 2008 May 15;14(10):3044-51
18483370
Blood. 2015 Jul 9;126(2):203-11
25800048
Mol Cancer Ther. 2015 Apr;14(4):847-56
25695955
Virchows Arch. 2014 Sep;465(3):351-8
25011996
Blood. 2013 Feb 28;121(9):1612-21
23247726
N Engl J Med. 2013 Jul 11;369(2):134-44
23724846
N Engl J Med. 2015 Jan 22;372(4):320-30
25399552
Eur J Haematol. 2013 Apr;90(4):286-90
23331211
Hum Pathol. 2009 Dec;40(12):1715-22
19695683
Nat Immunol. 2001 Mar;2(3):261-8
11224527
N Engl J Med. 2015 Jun 25;372(26):2521-32
25891173
Clin Cancer Res. 2013 Jul 1;19(13):3462-73
23674495
Eur J Surg Oncol. 2015 Apr;41(4):450-6
25682184
J Clin Oncol. 2014 Apr 1;32(10):1020-30
24590637
Histopathology. 2016 Jun;68(7):1079-89
26426431
Annu Rev Immunol. 2008;26:677-704
18173375
Nature. 2000 Feb 3;403(6769):503-11
10676951
Lancet Oncol. 2014 Jan;15(1):69-77
24332512
Leukemia. 2014 Dec;28(12):2367-75
24732592
Nature. 2014 Nov 27;515(7528):558-62
25428503
Blood. 1996 Feb 15;87(4):1571-8
8608249
Haematologica. 2014 Apr;99(4):715-25
24510338
PLoS One. 2015 Jun 26;10(6):e0131403
26114883
Clin Cancer Res. 2011 Jul 1;17(13):4232-44
21540239
Br J Haematol. 2007 May;137(4):364-73
17456059
Medicine (Baltimore). 2015 Feb;94(6):e515
25674748
N Engl J Med. 2015 May 21;372(21):2018-28
25891174
Oncotarget. 2015 Aug 14;6(23):19393-404
26305724
Leuk Lymphoma. 2012 Sep;53(9):1785-94
22397719
Nat Commun. 2016 Feb 17;7:10501
26883990
PLoS One. 2012;7(4):e35178
22532845
J Clin Oncol. 2009 Mar 20;27(9):1470-6
19224853
N Engl J Med. 2015 Jul 2;373(1):23-34
26027431
N Engl J Med. 2002 Jun 20;346(25):1937-47
12075054
Leukemia. 2016 Mar;30(3):570-9
26522085
Blood. 2008 Mar 15;111(6):3220-4
18203952
Am J Surg Pathol. 2006 Jul;30(7):802-10
16819321
Am Soc Clin Oncol Educ Book. 2015;:e458-66
25993210
Annu Rev Immunol. 2011;29:621-63
21314428
N Engl J Med. 2012 Jun 28;366(26):2455-65
22658128
Clin Cancer Res. 2010 Jan 15;16(2):637-50
20068089
Tumour Biol. 2016 Jun;37(6):7507-14
26678894
Blood. 2013 Jan 31;121(5):734-44
23223433